2024 annual financial data
Spero Therapeutics 2024 Operating margin
Spero Therapeutics 2024 operating margin with verified reported values.
Direct answer
Operating margin was -152.91%.
Operating income was -73,361,000 USD and net income was -68,566,000 USD.
Operating cash flow was -23,444,000 USD.
Get free Spero Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 47,977,000 USD
- Operating income
- -73,361,000 USD
- Net income
- -68,566,000 USD
- Operating cash flow
- -23,444,000 USD